Parecoxib

{{Drugbox | Verifiedfields = changed | verifiedrevid = 464197422 | IUPAC_name = N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]
sulfonyl}propanamide | image =Parecoxib.png

| tradename = | Drugs.com = International Drug Names | licence_EU = Dynastat | pregnancy_category = Not recommended | legal_AU = S4 | legal_UK = POM | routes_of_administration = Intravenous and intramuscular

| bioavailability = 100% | protein_bound = 98% | metabolism = Hepatic to valdecoxib and propionic acid
CYP extensively involved (mainly CYP3A4 and 2C9) | elimination_half-life = 22 minutes (parecoxib)
8 hours (valdecoxib) | excretion = Renal (70%, metabolites)

| CAS_number_Ref =  ^Y | CAS_number = 202409-33-4 | ATC_prefix = M01 | ATC_suffix = AH04 | PubChem = 119828 | DrugBank_Ref =  ^Y | DrugBank = DB08439 | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 106990 | UNII_Ref =  ^Y | UNII = 9TUW81Y3CE | ChEBI_Ref =  ^N | ChEBI = 73038 | ChEMBL_Ref =  ^N | ChEMBL = 1206690

| C=19 | H=18 | N=2 | O=4 | S=1 | molecular_weight = 370.422 g/mol | smiles = O=C(NS(=O)(=O)c3ccc(c2c(onc2c1ccccc1)C)cc3)CC | InChI = 1/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) | InChIKey = TZRHLKRLEZJVIJ-UHFFFAOYAA | StdInChI_Ref =  ^Y | StdInChI = 1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22) | StdInChIKey_Ref =  ^Y | StdInChIKey = TZRHLKRLEZJVIJ-UHFFFAOYSA-N }}

WikiDoc Resources for Parecoxib
Articles
Most recent articles on Parecoxib Most cited articles on Parecoxib Review articles on Parecoxib Articles on Parecoxib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Parecoxib Images of Parecoxib Photos of Parecoxib Podcasts & MP3s on Parecoxib Videos on Parecoxib
Evidence Based Medicine
Cochrane Collaboration on Parecoxib Bandolier on Parecoxib TRIP on Parecoxib
Clinical Trials
Ongoing Trials on Parecoxib at Clinical Trials.gov Trial results on Parecoxib Clinical Trials on Parecoxib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Parecoxib NICE Guidance on Parecoxib NHS PRODIGY Guidance FDA on Parecoxib CDC on Parecoxib
Books
Books on Parecoxib
News
Parecoxib in the news Be alerted to news on Parecoxib News trends on Parecoxib
Commentary
Blogs on Parecoxib
Definitions
Definitions of Parecoxib
Patient Resources / Community
Patient resources on Parecoxib Discussion groups on Parecoxib Patient Handouts on Parecoxib Directions to Hospitals Treating Parecoxib Risk calculators and risk factors for Parecoxib
Healthcare Provider Resources
Symptoms of Parecoxib Causes & Risk Factors for Parecoxib Diagnostic studies for Parecoxib Treatment of Parecoxib
Continuing Medical Education (CME)
CME Programs on Parecoxib
International
Parecoxib en Espanol Parecoxib en Francais
Business
Parecoxib in the Marketplace Patents on Parecoxib
Experimental / Informatics
List of terms related to Parecoxib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. However, unlike ketorolac, parecoxib has no effect on platelet function and therefore does not promote bleeding during or after surgery. In addition, ketorolac has a much higher gastrointestinal toxicity profile compared to most other nonsteroidal antiinflammatory drugs (NSAIDs) including ibuprofen and naprosyn. However, in the United States ketorolac is the only injectable NSAID, although it is banned in many European countries due to concerns about surgical bleeding and stomach ulcers after surgery.

In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States. No reasons were ever documented publicly for the non-approval, although one study noted increased occurrences of heart attacks following cardiac bypass surgery compared to placebo when high doses of parecoxib were used to control pain after surgery. It is also important to remember that rare but severe allergic reactions (Stevens-Johnson Syndrome, Lyell Syndrome) have been described with valdecoxib, the molecule to which parecoxib is converted. The drug is not approved for use after cardiac surgery in Europe. Ketorolac, still banned in much of Europe, and IV Ibuprofen are therefore the only options for IV NSAIDs in the United States, and it is not clear whether parecoxib will be resubmitted to the FDA in the future.

All anti-inflammatory medications in the U.S. carry the same warning regarding skin reactions, and none are approved for use during CABG surgery, so the reason for the FDA denying the approval of parecoxib remains unknown, but was likely related to political pressure from the US Congress to not approve another COX-2 selective inhibitor in the wake of the Vioxx affair. No COX-2 selective inhibitor has been approved in the US since that time, regardless of the safety profile of parecoxib in Europe. Efforts to find out the scientific rationale, or more likely the lack thereof, that the FDA used to justify the non-approval of parecoxib in the USA have proven futile due to secrecy issues.

Further reading

• Acta Ortop Mex. 2009Nov-Dec;23(6): 342-50 .[Systematic review to assess the effectiveness and safety of parecoxib].[Article in Spanish]Villasís-KeeverMA, Rendón-MacíasME, Escamilla-NúñezA.
• CochraneDatabase Syst Rev. 2009 Apr 15;(2):CD004771. doi: 10.1002/14651858.CD004771.pub4.Intravenous or intramuscular parecoxib for acute postoperative painin adults. Lloyd R, Derry S, Moore RA, McQuay HJ

See also

• COX-2 selective inhibitor
• Valdecoxib